The World Health Organisation Classification Of Myelodysplastic Syndromes Contains Prognostically Relevant Information Beyond The Prognostic Scores Ipss-r Or Wpss by Metze, K. et al.
UNIVERSIDADE ESTADUAL DE CAMPINAS
SISTEMA DE BIBLIOTECAS DA UNICAMP
REPOSITÓRIO DA PRODUÇÃO CIENTIFICA E INTELECTUAL DA UNICAMP
Versão do arquivo anexado / Version of attached file:
Versão do Editor / Published Version
Mais informações no site da editora / Further information on publisher's website:
https://www.sciencedirect.com/science/article/pii/S0959804916330672
DOI: 10.1016/j.ejca.2016.11.030
Direitos autorais / Publisher's copyright statement:
©2017 by Elsevier Sci Ltd. All rights reserved.
DIRETORIA DE TRATAMENTO DA INFORMAÇÃO
Cidade Universitária Zeferino Vaz Barão Geraldo
CEP 13083-970 – Campinas SP
Fone: (19) 3521-6493
http://www.repositorio.unicamp.br
European Journal of Cancer 72 (2017) 266e268Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer.comLetter to the EditorThe World Health Organisation classification of
myelodysplastic syndromes contains prognostically relevant
information beyond the prognostic scores IPSS-R or WPSSKonradin Metze a,*, Suiellen C. Reis-Alves b, Irene Lorand-Metze ba Department of Pathology, University of Campinas, São Paulo, Brazil
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In their interesting retrospective study, van Spronsen
et al. [1] compared the prognostic relevance of the FAB
and WHO classifications with the IPSS-R score in MDS
patients and concluded that the morphological classifi-
cation models were of no prognostic relevance beyond
the revised International Prognostic Score System
(IPSS-R). The authors performed survival analyses
with KaplaneMeier-plots, log-rank tests and multivar-
iate Cox regressions, to examine whether morphological
classification models could add prognostic value to
IPSS-R. However, some methodological details are
missing in their paper. Most probably they have used
stepwise selection procedures for the multivariate Cox
analyses. Since the user can choose among several var-
iable selection algorithms in the SPSS program, different
final models may be created. Moreover, very small sta-
tistical fluctuations of the data could be relevant for the
choice of the final Cox model. In the light of theseDOIs of original article: http://dx.doi.org/10.1016/j.ejca.2015.12.004,
http://dx.doi.org/10.1016/j.ejca.2016.11.029.
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0959-8049/ª 2016 Elsevier Ltd. All rights reserved.methodological uncertainties, and the provoking sug-
gestion to stop the use of morphological classification
models for MDS risk stratification, we decided to
reanalyse our own data of 101 MDS patients [2e5]. In
this prospective cohort, only patients with high risk
disease had been treated by cytotoxic therapy. All other
patients had received only supportive care. Patients with
chemotherapy or BM transplantation had been censored
at beginning of the treatment.
First, we calculated univariate Cox models for overall
survival until May 2016, stratifying according to FAB,
WHO, IPSS-R or WHO classification-based Prognostic
Score System (WPSS). In multivariate Cox regressions,
we compared the following pairwise combinations:
WHO/IPSS-R, WHO/WPSS, FAB/IPSS-R and FAB/
WPSS using the backward selection algorithm (pZ 0.05
for inclusion and p Z 0.10 for exclusion). The Akaike
information criterion (AIC) and its relative weight (w),
both based on the maximised log-likelihood and the
number of parameters in the Cox regressions, were
calculated to estimate the discriminatory power of these
models and their relative goodness-of-fit regarding the
overall survival curve [3,4]. Lower AIC or higher w
values are equivalent to better explanatory power of the
model. The internal stability was evaluated by bootstrap
resampling, where 100 new data sets with identical
sample size were created by random sampling from the
pool of original data with replacement. Then, Cox
Table 1
Akaike information criteria derived from variables regarding overall survival for MDS classifications and their combinations regarding original
data.
FAB WHO IPSS-R WPSS WHO þ IPSS-R WHO þ WPSS
AIC 323.91 318.64 309.50 309.27 305.17 301.86
Relative AIC weights 0.000 0.000 0.018 0.02 0.154 0.808
Significant Cox models in bootstrap sets 100% 100% 100% 100% 84% 94%
Abbreviations: WHO, World Health Organisation; AIC, Akaike information criteria.
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conditions as the calculations of the original data [2,6].
Finally, we compared the AIC values in the bootstrap
sets by analysis of variance for repeated measures and
the paired t test with correction of the alpha error by
Cross and Chaffin [7].
Median observation time of the patients was 48
months. In May 2016, 52 patients were still alive. Pa-
tients had a median age of 64 years at diagnosis (range
15e93 years). According to the FAB classification, 56
cases were refractory anaemia, 17 were refractory
anaemia with ring sideroblasts, 28 were refractory
anaemia with excess of blasts and 4 refractory anaemia
with excess of blasts in transformation. Cases of chronic
myelomonocytic leukaemia were not included. Ac-
cording to the WHO 2008 criteria, there were 2 patients
with 5q-syndrome, 7 with refractory cytopenias, 64 with
refractory cytopenias with multilineage dysplasias and
28 with refractory anaemia with excess of blasts. Clas-
sifying according to the IPSS-R score, we found 14 very
low risk, 40 low risk, 23 intermediate risk, 17 high risk,
as well as, 7 very high risk patients. When applying the
WPSS classification system, there were 3 patients with
very low risk, 28 with low risk, 36 with intermediate
risk, 22 with high risk and 6 with very high risk.
All four classifications discriminated significantly
(p < 0.05) survival in univariate Cox regressions. This
was also the case for the combinations WHO/IPSS-
R and WHO/WPSS, but not for FAB/IPSS-R and FAB/
WPSS combinations. In 100 bootstrap resampling sets,
this was also true for the overwhelming majority of the
cases (Table 1), whereas the combinations FAB/IPSS-R
and FAB/WPSS yielded significant multivariate models
in only 17% and 21% of the 100 sets, respectively and
were therefore not considered in further evaluations.
AIC values of IPSS-R and WPSS were lower than
those of the FAB and WHO classifications, and lowest
for the combinations WHO/IPSS-R and WHO/WPSS,
thus indicating that IPSS-R and WPSS explained better
the survival curve than the FAB or WHO classification.
The combinations WHO/IPSS-R and WHO/WPSS
yielded the best prognostic information.
According to the original data, the models based on
WPSS alone or in combination with the WHO classifi-
cation seemed to be superior to those using IPSS-R. But
this could be due to statistical fluctuations, since some-
times very few cases may be important for the modelselection. To detect this effect, we compared the AIC
values in the 100 bootstrap sets. Now the results of the
original data set were confirmed in so far as the WHO
classification had significant lower AICs than the FAB
classification. Better values were found for IPSS-R and
WPSS, but the best explanatory power was observed for
the combinations WHO/IPSS-R and WHO/WPSS.
In the 100 resampling data sets, the AICs of IPSS-R
scores were not significantly different from those of
WPSS scores and in the same way, there were no sig-
nificant differences between the AICs of the combined
Cox regressions WHO/IPSS-R and WHO/WPSS,
although this had been suggested by w values of the
original data.
Thus our prospective study showed that IPSS-R
and WPSS explain better the overall survival of MDS
patients than the stratification according to the diag-
nostic classifications, thus confirming a part of the
results of van Spronsen et al [1]. But our data also
revealed that combined models containing the WHO
2008 classification yielded significantly better models
than those based on a single classification. All these
results were corroborated in a bootstrap resampling
study, which underlines the stability of these models.
We were, however, not able to show a relevant dif-
ference of the explanatory power between IPSS-R and
WPSS, applied as a single variable or when combined
with the WHO classification.
Therefore we conclude that, based on the Akaike
information criteria, the WHO classification contains
prognostically relevant information beyond IPSS-R or
WPSS, at least regarding overall survival.
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